Treatment Response Biomarkers for Systemic Sclerosis–Associated Interstitial Lung Disease
Changes in the circulating levels of KL-6 after treatment with MMF or CYC predicted PPF, even after adjusting for baseline factors associated with PPF. Measuring longitudinal KL-6 in patients with SSc-ILD may improve how we personalize therapy in patients with SSc-ILD.
Authors
- Michael D. Roth (ORCID: https://orcid.org/0000-0003-2194-6578)
- Elizabeth R. Volkmann (ORCID: https://orcid.org/0000-0003-3750-6569)
- Holly Wilhalme (ORCID: https://orcid.org/0000-0001-9908-6219)
- Shervin Assassi (ORCID: https://orcid.org/0000-0002-8059-9978)
- Alana Haussmann
- Jonathan Goldin (ORCID: https://orcid.org/0000-0003-3007-9947)
- Donald P. Tashkin (ORCID: https://orcid.org/0000-0002-5607-4872)
- Grace Hyun J. Kim (ORCID: https://orcid.org/0000-0003-1225-3489)
- Masataka Kuwana (ORCID: https://orcid.org/0000-0001-8352-6136)
Institutions
- University of California, Los Angeles (US)
- Nippon Medical School (JP)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Arthritis Care & Research
- Published
- 2024-12-23
- DOI
- https://doi.org/10.1002/acr.25485
- Citations
- 5
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- U.S. Department of Defense
- National Institutes of Health
- National Heart, Lung, and Blood Institute